Newly Diagnosed Multiple Myeloma in Patients Under 70 Years of Age With No Comorbidities

This protocol addresses treatment in fit, newly diagnosed patients who are under 70 years of age, have no significant comorbidities, and are eligible for high-dose therapy and autologous stem cell transplantation.

Clinical Scenario

Newly diagnosed multiple myeloma; age under 70 years; no comorbidities; eligible for high-dose therapy (HDT) and autologous stem cell transplantation (ASCT). Fitness for transplant and absence of comorbidities are the defining eligibility criteria for this pathway.

Treatment Approach — Partial Overview

The protocol covers management across multiple treatment lines, including a range of combination regimen options for later-line settings that depend on prior therapy exposure, response, and disease-specific characteristics.

Full regimen detail, treatment sequencing, and selection criteria are available in the complete structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

For fit NDMM patients, aged <70 years, without comorbidities, induction followed by high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) and lenalidomide maintenance is the recommended treatment.
For patients who have been exposed or are refractory to both bortezomib and lenalidomide, DaraKd [I, A], IsaPd [I, A], IsaKd [I, A] and EloPd [II, B] are recommended.
Patients with t(11;14), who are refractory to lenalidomide and are PI-sensitive may be treated with VenVd [I, A], if available.
For triple-class refractory patients, Sd or belantamab mafodotin monotherapy is recommended [II, B], if available.

DOI: 10.1016/j.annonc.2020.11.014 View source ↗